ERBB2 and breast carcinoma: Moreover, identifying signaling molecules that can be effectively co-targeted such as HUNK kinase, which we demonstrate here can have an additive effect on impairing tumor growth when paired with SP600125, could be an effective strategy in treating HER2+ breast cancers that have become resistant to HER2 inhibition.